Boehinger’s Spiriva gets UK license for young asthma patients
Boehringer Ingelheim’s Spiriva Respimat is now licensed for use in the UK to treat people with asthma aged six years and older.
The therapy can be prescribed as add-on maintenance bronchodilator treatment in young patients with severe asthma who have experienced one or more severe asthma exacerbations in the past year.
The firm notes that the UK has one of the highest prevalence rates for paediatric asthma worldwide, with one in 11 children affected, while it is estimated that a child is admitted to hospital every 20 minutes because of an asthma attack.
Sprivia (triotropium respimat) is part of a class of medicines called long-acting muscarinic antagonists (LAMA), and works by preventing the air passages closing, improving airflow in and out of the lungs.
Read more: http://www.pharmatimes.com/news/boehingers_spiriva_gets_uk_license_for_young_asthma_patients_1238993
The therapy can be prescribed as add-on maintenance bronchodilator treatment in young patients with severe asthma who have experienced one or more severe asthma exacerbations in the past year.
The firm notes that the UK has one of the highest prevalence rates for paediatric asthma worldwide, with one in 11 children affected, while it is estimated that a child is admitted to hospital every 20 minutes because of an asthma attack.
Sprivia (triotropium respimat) is part of a class of medicines called long-acting muscarinic antagonists (LAMA), and works by preventing the air passages closing, improving airflow in and out of the lungs.
Read more: http://www.pharmatimes.com/news/boehingers_spiriva_gets_uk_license_for_young_asthma_patients_1238993